Ultraschall in der Medizin - European Journal of Ultrasound, Inhaltsverzeichnis

Ultraschall Med 2013; 34(1): 38-46
DOI: 10.1055/s-0032-1330387

Original Article

© Georg Thieme Verlag KG Stuttgart · New York

Early Response to Anti-Tumoral Treatment in Hepatocellular Carcinoma – Can Quantitative Contrast-Enhanced Ultrasound Predict Outcome?

Frühes Ansprechen auf antitumorale Therapie des hepatozellulären Karzinoms – Kann die quantitative Kontrastmittelsonografie das Outcome vorhersagen?

F. Knieling^*

¹Medizinische Klinik 1 – Gastroenterologie, Pneumologie und Endokrinologie, Universität Erlangen

,

M. J. Waldner^*

¹Medizinische Klinik 1 – Gastroenterologie, Pneumologie und Endokrinologie, Universität Erlangen

,

R. S. Goertz

¹Medizinische Klinik 1 – Gastroenterologie, Pneumologie und Endokrinologie, Universität Erlangen

,

S. Zopf

¹Medizinische Klinik 1 – Gastroenterologie, Pneumologie und Endokrinologie, Universität Erlangen

,

D. Wildner

¹Medizinische Klinik 1 – Gastroenterologie, Pneumologie und Endokrinologie, Universität Erlangen

,

M. F. Neurath

¹Medizinische Klinik 1 – Gastroenterologie, Pneumologie und Endokrinologie, Universität Erlangen

,

T. Bernatik

²Innere Medizin, Kreisklinik Ebersberg

,

D. Strobel

¹Medizinische Klinik 1 – Gastroenterologie, Pneumologie und Endokrinologie, Universität Erlangen

› Institutsangaben

Abstract

Purpose: In order to detect an early response to anti-angiogenic therapy, this study aims at analyzing specific effects of a sorafenib-based regime on intra-tumoral D-CEUS flow parameters of patients with HCC.

Materials and Methods: Videos of the arterial phase were captured before initiation of a therapy with sorafenib and 1 and 3 months after (n = 9). Patients receiving a non-anti-angiogenic therapy (TACE, n = 10) served as a comparison group. Cross-sectional imaging was performed at the same time points and patients were followed up for 1 year.

Results: In the responder group (RE), the absolute (percentage) TTP was 11.28 s ± 2.03 s (1.00) before treatment, 13.60 s ± 1.52 s (1.53 ± 0.08) after one month (p = 0.0405), and 16.17 s ± 2.35 s (1.46 ± 0.07) after three months of treatment (p = 0.0071). The TTP increased significantly in the RE group as early as 1 month after initiation of sorafenib compared to the non-responder group. There were no significant differences in the non-responder group or between the NR and the TACE group at any time point. D-CEUS values from all sorafenib-treated patients showed good accordance with RECICL (response evaluation criteria in cancer of the liver) criteria (R² = 0.7154, p = 0.0001).

Conclusions: Quantitative CEUS reveals variations of dynamic parameters of blood flow during anti-tumoral therapy in liver cancer patients. Further investigations and clinical trails have to confirm that the TTP is a promising parameter in the prediction of early response to sorafenib-based therapy.

Zusammenfassung

Ziel: Diese Studie versucht, Hinweise für ein frühes Therapieansprechen zu erhalten, indem die Einflüsse der dynamischen Flussparameter von D-CEUS auf eine anti-angiogenetische Therapie mit Sorafenib bei HCC analysieren werden.

Material und Methoden: Es wurden die Videosequenzen der arteriellen Anflutungsphase jeweils vor und 1 bzw. 3 Monate nach Beginn der Therapie mit Sorafenib (n = 9) aufgezeichnet. Als Vergleich dienten Patienten, die eine nicht anti-angiogenetische Therapie (TACE, n = 10) erhielten. Schnittbildgebung und eine Beobachtung über ein Jahr erfolgten.

Ergebnisse: In der Responder-Gruppe (RE) ergab sich ein absoluter (prozentualer) Anstieg der TPP von 11,28 s ± 2,03 s (1,00) auf 13,60 s ± 1,52 s (1,53 ± 0,08) nach 1 Monat (p = 0,0405) und 16,17 s ± 2,35 s (1,46 ± 0,07) nach 3 Monaten Therapie (p = 0,0071). Die TTP stiegt in der RE-Gruppe, im Gegensatz zur Non-Responder(NR)-Gruppe, innerhalb eines Monats nach Start der Therapie mit Sorafenib signifikant an. Weiterhin ergaben sich keine signifikanten Unterschiede in der Non-Responder-Gruppe oder zwischen der NR- und der TACE-Gruppe zu den Beobachtungszeitpunkten. Die D-CEUS-Werte von allen Sorafenib-Patienten zeigten eine gute Übereinstimmung mit den RECICL(Response Evaluation Criteria in Cancer of the Liver)-Kriterien (R² = 0,7154, p = 0,0001).

Schlussfolgerung: Die quantitative CEUS zeigt Veränderungen der dynamischen Durchblutungsparameter während unterschiedlichen Therapieformen in Patienten mit hepatozellulären Karzinomen. Weitere Untersuchungen und klinische Studien müssen zeigen, ob die TTP ein vielversprechender Parameter für die Vorhersage des frühen Ansprechens auf eine Sorafenib-Therapie sein kann.

Key words

Key words

abdomen - angiogenesis - microbubbles - ultrasound - tumor

References
1 Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100: 57-70
2 Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971; 285: 1182-1186
3 Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature 2000; 407: 249-257
4 Waldner MJ, Wirtz S, Jefremow A et al. VEGF receptor signaling links inflammation and tumorigenesis in colitis-associated cancer. J Exp Med 2010; 207: 2855-2868
5 Bruix J, Sherman M. Management of hepatocellular carcinoma: An update. Hepatology 2011; 53: 1020-1022
6 Llovet JM, Ricci S, Mazzaferro V et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359: 378-390
7 World Health Organization. WHO handbook for reporting results of cancer treatment. Geneva: World Health Organization; 1979
8 Miller AB, Hoogstraten B, Staquet M et al. Reporting results of cancer treatment. Cancer 1981; 47: 207-214
9 Eisenhauer EA, Therasse P, Bogaerts J et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). European Journal of Cancer 2009; 45: 228-247
10 Kudo M, Kubo S, Takayasu K et al. Response Evaluation Criteria in Cancer of the Liver (RECICL) proposed by the Liver Cancer Study Group of Japan (2009 Revised Version). Hepatol Res 2010; 40: 686-692
11 Llovet JM, Di Bisceglie AM, Bruix J et al. Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst 2008; 100: 698-711
12 Hurwitz H, Fehrenbacher L, Novotny W et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350: 2335-2342
13 Shepherd FA, Rodrigues Pereira J, Ciuleanu T et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005; 353: 123-132
14 Hudes G, Carducci M, Tomczak P et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007; 356: 2271-2281
15 Lassau N, Koscielny S, Albiges L et al. Metastatic renal cell carcinoma treated with sunitinib: early evaluation of treatment response using dynamic contrast-enhanced ultrasonography. Clin Cancer Res 2010; 16: 1216-1225
16 Lassau N, Chami L, Chebil M et al. Dynamic contrast-enhanced ultrasonography (DCE-US) and anti-angiogenic treatments. Discov Med 2011; 11: 18-24
17 Lassau N, Koscielny S, Chami L et al. Advanced hepatocellular carcinoma: early evaluation of response to bevacizumab therapy at dynamic contrast-enhanced US with quantification – preliminary results. Radiology 2011; 258: 291-300
18 Lassau N, Lamuraglia M, Chami L et al. Gastrointestinal stromal tumors treated with imatinib: monitoring response with contrast-enhanced sonography. Am J Roentgenol Am J Roentgenol 2006; 187: 1267-1273
19 Yoshida K, Hirokawa T, Moriyasu F et al. Arterial-phase contrast-enhanced ultrasonography for evaluating anti-angiogenesis treatment: a pilot study. World J Gastroenterol 2011; 17: 1045-1050
20 Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology 2005; 42: 1208-1236
21 Claudon M, Cosgrove D, Albrecht T et al. Guidelines and good clinical practice recommendations for contrast enhanced ultrasound (CEUS) – update 2008. Ultraschall in Med 2008; 29: 28-44
22 Soder RB, Baldisserotto M, Duval da Silva V. Computer-assisted ultrasound analysis of liver echogenicity in obese and normal-weight children. Am J Roentgenol 2009; 192: W201-W205
23 Ignee A, Jedrejczyk M, Schuessler G et al. Quantitative contrast enhanced ultrasound of the liver for time intensity curves-Reliability and potential sources of errors. Eur J Radiol 2010; 73: 153-158
24 Heidenreich PA, Wiencek JG, Zaroff JG et al. In vitro calculation of flow by use of contrast ultrasonography. J Am Soc Echocardiogr 1993; 6: 51-61
25 Schwarz KQ, Bezante GP, Chen X et al. Volumetric arterial flow quantification using echo contrast. An in vitro comparison of three ultrasonic intensity methods: radio frequency, video and Doppler. Ultrasound Med Biol 1993; 19: 447-460
26 Correas JM, Burns PN, Lai X et al. Infusion versus bolus of an ultrasound contrast agent: in vivo dose-response measurements of BR1. Invest Radiol 2000; 35: 72-79
27 Claassen L, Seidel G, Algermissen C. Quantification of flow rates using harmonic grey-scale imaging and an ultrasound contrast agent: an in vitro and in vivo study. Ultrasound Med Biol 2001; 27: 83-88
28 Jaffe CC. Measures of response: RECIST, WHO, and new alternatives. J Clin Oncol 2006; 24: 3245-3251
29 Choi H, Charnsangavej C, de Castro Faria S et al. CT evaluation of the response of gastrointestinal stromal tumors after imatinib mesylate treatment: a quantitative analysis correlated with FDG PET findings. Am J Roentgenol 2004; 183: 1619-1628
30 Forner A, Ayuso C, Varela M et al. Evaluation of tumor response after locoregional therapies in hepatocellular carcinoma: are response evaluation criteria in solid tumors reliable?. Cancer 2009; 115: 616-623
31 Lee CH, Braga L, de Campos RO et al. Hepatic tumor response evaluation by MRI. NMR Biomed 2011; 24: 721-733
32 Hittinger M, Staehler M, Schramm N et al. Course of size and density of metastatic renal cell carcinoma lesions in the early follow-up of molecular targeted therapy. Urol Oncol 2011;
33 Abou-Alfa GK, Schwartz L, Ricci S et al. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol 2006; 24: 4293-4300
34 Horger M, Lauer UM, Schraml C et al. Early MRI response monitoring of patients with advanced hepatocellular carcinoma under treatment with the multikinase inhibitor sorafenib. BMC Cancer 2009; 9: 208
35 Carmeliet P, Jain RK. Molecular mechanisms and clinical applications of angiogenesis. Nature 2011; 473: 298-307
36 de Langen AJ, van den Boogaart V, Lubberink M et al. Monitoring response to antiangiogenic therapy in non-small cell lung cancer using imaging markers derived from PET and dynamic contrast-enhanced MRI. J Nucl Med 2011; 52: 48-55
37 Siegel AB, Cohen EI, Ocean A et al. Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma. J Clin Oncol 2008; 26: 2992-2998
38 Sunaga N, Oriuchi N, Kaira K et al. Usefulness of FDG-PET for early prediction of the response to gefitinib in non-small cell lung cancer. Lung Cancer 2008; 59: 203-210
39 Hamstra DA, Rehemtulla A, Ross BD. Diffusion magnetic resonance imaging: a biomarker for treatment response in oncology. J Clin Oncol 2007; 25: 4104-4109
40 O’Connor JP, Jackson A, Parker GJ et al. DCE-MRI biomarkers in the clinical evaluation of antiangiogenic and vascular disrupting agents. Br J Cancer 2007; 96: 189-195
41 Verheul HM, Pinedo HM. Possible molecular mechanisms involved in the toxicity of angiogenesis inhibition. Nat Rev Cancer 2007; 7: 475-485
42 Jubb AM, Harris AL. Biomarkers to predict the clinical efficacy of bevacizumab in cancer. Lancet Oncol 2010; 11: 1172-1183
43 Veronese ML, Mosenkis A, Flaherty KT et al. Mechanisms of hypertension associated with BAY 43-9006. J Clin Oncol 2006; 24: 1363-1369
44 Robinson ES, Matulonis UA, Ivy P et al. Rapid development of hypertension and proteinuria with cediranib, an oral vascular endothelial growth factor receptor inhibitor. Clin J Am Soc Nephrol 2010; 5: 477-483
45 Bhargava P. VEGF kinase inhibitors: how do they cause hypertension?. Am J Physiol Regul Integr Comp Physiol 2009; 297: R1-R5
46 Li B, Ogasawara AK, Yang R et al. KDR (VEGF receptor 2) is the major mediator for the hypotensive effect of VEGF. Hypertension 2002; 39: 1095-1100
47 Steeghs N, Gelderblom H, Roodt JO et al. Hypertension and rarefaction during treatment with telatinib, a small molecule angiogenesis inhibitor. Clin Cancer Res 2008; 14: 3470-3476
48 Strobel D, Seitz K, Blank W et al. Tumor-specific vascularization pattern of liver metastasis, hepatocellular carcinoma, hemangioma and focal nodular hyperplasia in the differential diagnosis of 1,349 liver lesions in contrast-enhanced ultrasound (CEUS). Ultraschall in Med 2009; 30: 376-382
49 Guang Y, Xie L, Ding H et al. Diagnosis value of focal liver lesions with SonoVue^®-enhanced ultrasound compared with contrast-enhanced computed tomography and contrast-enhanced MRI: a meta-analysis. J Cancer Res Clin Oncol 2011; 137: 1595-1605
50 Moriyasu F, Itoh K. Efficacy of perflubutane microbubble-enhanced ultrasound in the characterization and detection of focal liver lesions: phase 3 multicenter clinical trial. Am J Roentgenol 2009; 193: 86-95
51 Tranquart F, Correas JM, Ladam Marcus V et al. Real-time contrast-enhanced ultrasound in the evaluation of focal liver lesions: diagnostic efficacy and economical issues from a French multicentric study. J Radiol 2009; 90: 109-122
52 Trillaud H, Bruel JM, Valette PJ et al. Characterization of focal liver lesions with SonoVue-enhanced sonography: international multicenter-study in comparison to CT and MRI. World J Gastroenterol 2009; 15: 3748-3756
53 Bernatik T, Becker D, Neureiter D et al. Detection of liver metastases – comparison of contrast-enhanced ultrasound using first versus second generation contrast agents. Ultraschall in Med 2003; 24: 175-179
54 Strobel D, Kleinecke C, Hansler J et al. Contrast-enhanced sonography for the characterisation of hepatocellular carcinomas – correlation with histological differentiation. Ultraschall in Med 2005; 26: 270-276
55 Strobel D, Seitz K, Blank W et al. Contrast-enhanced ultrasound for the characterization of focal liver lesions – diagnostic accuracy in clinical practice (DEGUM multicenter trial). Ultraschall in Med 2008; 29: 499-505
56 Romanini L, Passamonti M, Aiani L et al. Economic assessment of contrast-enhanced ultrasonography for evaluation of focal liver lesions: a multicentre Italian experience. Eur Radiol 2007; 17: F99-F106
57 Giesel FL, Delorme S, Sibbel R et al. Contrast-enhanced ultrasound for the characterization of incidental liver lesions – an economical evaluation in comparison with multi-phase computed tomography. Ultraschall in Med 2009; 30: 259-268
58 Schuler A, Reuss J, Delorme S et al. Costs of clinical ultrasound examinations – an economical cost calculation and analysis. Ultraschall in Med 2010; 31: 379-386
59 Lassau N, Chami L, Benatsou B et al. Dynamic contrast-enhanced ultrasonography (DCE-US) with quantification of tumor perfusion: a new diagnostic tool to evaluate the early effects of antiangiogenic treatment. Eur Radiol 2007; 17: F89-F98
60 Lassau N, Lamuraglia M, Koscielny S et al. Prognostic value of angiogenesis evaluated with high-frequency and colour Doppler sonography for preoperative assessment of primary cutaneous melanomas: correlation with recurrence after a 5 year follow-up period. Cancer imaging: the official publication of the International Cancer Imaging Society 2006; 6: 24-29
61 Lamuraglia M, Escudier B, Chami L et al. To predict progression-free survival and overall survival in metastatic renal cancer treated with sorafenib: pilot study using dynamic contrast-enhanced Doppler ultrasound. European Journal of Cancer 2006; 42: 2472-2479
62 Egger C, Goertz RS, Strobel D et al. Dynamic Contrast-Enhanced Ultrasound (DCE-US) for Easy and Rapid Evaluation of Hepatocellular Carcinoma Compared to Dynamic Contrast-Enhanced Computed Tomography (DCE-CT) – A Pilot Study. Ultraschall in Med 2012; 33: 587-592
63 Dietrich CF, Averkiou MA, Correas JM et al. An EFSUMB introduction into Dynamic Contrast-Enhanced Ultrasound (DCE-US) for quantification of tumour perfusion. Ultraschall in Med 2012; 33: 344-351